Real-world metabolic outcomes of semaglutide use in patients with type 2 diabetes: a retrospective study from a single centre in the United Arab Emirates

2021 ◽  
Author(s):  
Matthew Allum ◽  
Adam Buckley ◽  
Nader Lessan ◽  
Nagi Mohammed ◽  
Mohamed Suliman ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Retrospective Study ◽  
United Arab Emirates ◽  
Real World ◽  
Single Centre ◽  
Metabolic Outcomes

scholarly journals Cardiovascular Profile of Patients with Type 2 Diabetes in France Based on REWIND CVOT Inclusion Criteria: A Real-World Retrospective Study

2022 ◽  
Author(s):  
Anne Dib ◽  
Florence Chartier ◽  
Katharina Ihle ◽  
Isabelle Jamonneau ◽  
Lisa Ludwig ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Retrospective Study ◽  
Real World ◽  
Inclusion Criteria ◽  
Cardiovascular Profile

scholarly journals Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study

2022 ◽  
Vol 12 (1) ◽  
Author(s):  
Kenichi Tanaka ◽  
Yosuke Okada ◽  
Akemi Tokutsu ◽  
Yoshiya Tanaka
Keyword(s):  
Type 2 Diabetes ◽  
Retrospective Study ◽  
Propensity Score ◽  
Real World ◽  
Linear Regression Analysis ◽  
Multivariate Linear Regression Analysis ◽  
Contributing Factors ◽  
Real World Data ◽  
Real World Setting

AbstractReal-world data comparing the effectiveness of various glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in type 2 diabetes mellitus (T2DM) are limited. We investigated the clinical effectiveness of liraglutide and dulaglutide in Japanese T2DM in a real-world setting. This retrospective study included 179 patients with T2DM who were treated with GLP-1 RA for at least 12 months (liraglutide, n = 97; dulaglutide, n = 82). We used stabilized propensity score-based inverse probability of treatment weighting (IPTW) to reduce selection bias and confounding by observed covariates. Changes in glycated hemoglobin (HbA1c) at the end of the 12-month treatment were evaluated. After adjustment by stabilized propensity score-based IPTW, no significant differences were observed in patient characteristics between the liraglutide and dulaglutide groups. HbA1c was significantly lower at 12 months in both groups (liraglutide, 8.9 to 7.4%; dulaglutide, 8.7 to 7.5%). Multivariate linear regression analysis showed no differences in the extent of changes in HbA1c at 12 months between the two agents. High baseline HbA1c, the addition of GLP-1 RA treatment modality, and in-hospital initiation of GLP-1 RA treatment were identified as significant contributing factors to HbA1c reduction. The effects of liraglutide and dulaglutide on lowering HbA1c levels at 12 months were comparable in a real-world setting.

scholarly journals Real-World Effectiveness of Liraglutide Versus Dulaglutide In Japanese Patients With Type 2 Diabetes: A Retrospective Study

2021 ◽  
Author(s):  
Kenichi Tanaka ◽  
Yosuke Okada ◽  
Akemi Tokutsu ◽  
Yoshiya Tanaka
Keyword(s):  
Type 2 Diabetes ◽  
Retrospective Study ◽  
Real World ◽  
Clinical Effectiveness ◽  
Patient Characteristics ◽  
Japanese Patients ◽  
Hierarchical Regression ◽  
Contributing Factors ◽  
Real World Data

Abstract Real-world data comparing the effectiveness of various glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in type 2 diabetes mellitus (T2DM) are limited. We investigated the clinical effectiveness of liraglutide and dulaglutide in Japanese T2DM in a real-world setting. This retrospective study included 179 patients with T2DM who were treated with GLP-1 RA for at least 12 months (liraglutide, n=97; dulaglutide, n=82). Changes in glycated hemoglobin (HbA1c) at the end of 12-month treatment were evaluated. Compared with the liraglutide group, the dulaglutide group included significantly older patients with longer disease duration, lower body mass index, and higher proportion of dementia cases. HbA1c was significantly lower at 12 months in both groups (liraglutide, 8.9 to 7.6%; dulaglutide, 8.8 to 7.5%). Hierarchical regression analysis showed no differences in the extent of changes in HbA1c at 12 months between the two agents, after adjustment for differences in patient characteristics and drug adjustments during the 12-month period. High baseline HbA1c, the addition of GLP-1 RA treatment, and in-hospital initiation of GLP-1 RA treatment were identified as significant contributing factors to HbA1c reduction. Although patient characteristics were different between the two treatment groups, comparable HbA1c-lowering effects were noted in real-world settings.

Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real-world retrospective study conducted in Spain

2018 ◽  
Vol 35 (11) ◽  
pp. 1605-1612 ◽  
Author(s):  
F. Gomez-Peralta ◽  
A. Lecube ◽  
A. Fernández-Mariño ◽  
I. Alonso Troncoso ◽  
C. Morales ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Retrospective Study ◽  
Real World ◽  
Clinical Effectiveness ◽  
Interindividual Differences

scholarly journals PDB114 - DRUG UTILIZATION STUDY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN AN ITALIAN REAL-WORLD SETTING: A RETROSPECTIVE STUDY

2018 ◽  
Vol 21 ◽  
pp. S137-S138
Author(s):  
L. Degli Esposti ◽  
V. Perrone ◽  
S. Saragoni ◽  
V. Blini ◽  
R. D'Avella ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Retrospective Study ◽  
Drug Utilization ◽  
Real World ◽  
Drug Utilization Study ◽  
Real World Setting
Sign in / Sign up

Export Citation Format

Share Document